{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-023162","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.520938+00:00","generated_at":"2026-06-11T15:53:22.594473+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Perspective Q2 net loss widens to $11.1M on 17% revenue drop; pipeline advances","bullets":["Q2 2023 revenue $2.1M (-17% YoY); net loss $11.1M vs $2.1M loss a year ago.","Cash and equivalents $28.5M at June 30, 2023, down from $43.9M at Dec 31, 2022.","Phase 1/2a trials initiated for VMT-α-NET (neuroendocrine) and VMT01 (melanoma); first patient dosed; preliminary data expected by end-2023.","New executives: Heidi Henson (Audit Chair), Andrew Bright (EVP Brachytherapy), Shane Cobb (EVP Operations).","Cesium-131 brachytherapy data showed 96% disease-free survival at 10 years for prostate cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-023162","json":"https://secwatch.observer/filing/0001437749-23-023162.json","markdown":"https://secwatch.observer/filing/0001437749-23-023162.md","text":"https://secwatch.observer/filing/0001437749-23-023162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774923023162/0001437749-23-023162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774923023162/isr20230809_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T15:53:22.594473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab8b9f2acc7efecbb5c0b38f19f5b0490e65519b","claim":"Perspective Therapeutics, Inc. reported financial results for second quarter of fiscal 2023 ended June 30, 2023.","evidence_excerpt":"On August 11, 2023, the Company issued a press release announcing its financial results for the second quarter of fiscal 2023 ended June 30, 2023, the text of which is attached hereto as Exhibit 99.1.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923023162/0001437749-23-023162-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of fiscal 2023 ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}